Cathepsin G (CTSG) is overexpressed and aberrantly localized for antigen presentation on acute myeloid leukemia blasts and stem cells compared to normal hematopoietic progenitors. Earlier this year, Crossbow Therapeutics Inc. announced the nomination of its first development candidate, CBX-250, a TCR-mimetic (TCRm) bispecific T-cell engager (TCE) antibody targeting a CTSG peptide-human leukocyte antigen (pHLA) complex and CD3.
Crossbow Therapeutics Inc. has nominated its first development candidate, CBX-250, a first-in-class, potent and specific T-cell engager (TCE) for the treatment of myeloid leukemia. CBX-250 targets a cathepsin G (CTSG) peptide-human leukocyte antigen (pHLA) complex abundantly expressed on leukemic cells, but not on normal cells.
